Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Brisbane, California. It specializes in the discovery, development and commercialization of targeted protein degradation medicines for cancer and autoimmune diseases. The company’s lead program is bexobrutideg (NX-5948), an oral, brain-penetrant BTK degrader currently advancing toward Phase 3 trials in chronic lymphocytic leukemia and other indications.
In June 2026, Nurix entered a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology and neurology. Under the agreement, Nurix receives an upfront payment of USD 700 million and is eligible for up to USD 2.3 billion in milestones, with shared U.S. profits and royalties outside the United States. Nurix also maintains collaborations with Gilead Sciences, Sanofi and Pfizer.
Official website: nurixtx.com
To provide comprehensive coverage, we aggregate data and news under the name Nurix, encompassing the following company names, divisions, and related entities:
Nurix Inc. and Kura Therapeutics, Inc..
This list encompasses current and former names, alternate names, and key divisions associated with Nurix, ensuring you can easily find all relevant information under a single, unified profile.
